Blood or marrow transplantation (BMT) is used with curative intent for hematologic malignancies. Conditional on surviving the first 2 years after BMT, 5-year survival generally exceeds 70%. However, the cumulative therapeutic exposures lead to premature onset of chronic health conditions, such that the 15-year cumulative incidence of severe or life-threatening chronic health conditions exceeds 40%, resulting in premature mortality. The high burden of morbidity, coupled with a long latency between BMT and the development of chronic health conditions necessitates life-long risk-based monitoring of the BMT survivors. The issues of how and when to screen BMT survivors for therapy-related complications and exacerbation of preexisting conditions are important and largely unanswered questions. For BMT survivors, screening recommendations must incorporate risks associated with pre-BMT therapy as well as risks related to transplant conditioning and graft-versus-host disease. Here, we describe our approach to monitoring BMT survivors for risk-based screening and early detection of key late-occurring or long-term complications using patient scenarios to illustrate our discussion.

Blood or marrow transplantation (BMT) is used with curative intent for hematologic malignancies. BMT recipients are exposed to chemotherapy and/or radiation before BMT (for management of primary cancer), at BMT (for the transplant procedure), and after BMT (for graft-versus-host disease [GVHD] management and/or relapse of primary cancer). The cumulative therapeutic exposures injure normal tissues, leading to premature onset of chronic health conditions such as subsequent neoplasms (SNs),1-3  congestive heart failure (CHF),4-6  coronary artery disease,7  and musculoskeletal abnormalities.8,9  In fact, the 15-year cumulative incidence of severe or life-threatening chronic health conditions exceeds 40%,10,11  resulting in premature mortality12-17  (Figure 1). Because BMT survivors carry an inordinately high burden of morbidity and because many long-term complications may not manifest for years or even decades after BMT, survivors are in need of ongoing, life-long monitoring.

Figure 1.

Late mortality after BMT. (A) Late mortality in 854 individuals who had survived 2 or more years after autologous BMT for hematological malignancies. Median age at BMT was 36.5 years and the median length of follow-up was 7.6 years. Overall survival was 68.8% at 10 years. Adapted from Bhatia et al.12  (B) Late mortality in 1479 individuals who had survived 2 or more years after allogeneic BMT. Median age at BMT was 25.9 years and median length of follow-up was 9.5 years. Conditional survival probability at 15 years was 80.2 years for those who remained disease-free at entry into the cohort. Adapted from Bhatia et al.13 

Figure 1.

Late mortality after BMT. (A) Late mortality in 854 individuals who had survived 2 or more years after autologous BMT for hematological malignancies. Median age at BMT was 36.5 years and the median length of follow-up was 7.6 years. Overall survival was 68.8% at 10 years. Adapted from Bhatia et al.12  (B) Late mortality in 1479 individuals who had survived 2 or more years after allogeneic BMT. Median age at BMT was 25.9 years and median length of follow-up was 9.5 years. Conditional survival probability at 15 years was 80.2 years for those who remained disease-free at entry into the cohort. Adapted from Bhatia et al.13 

Close modal

The issue of how and when to screen BMT survivors for complications is important, yet largely unaddressed. Recommendations for screening for BMT survivors have been developed jointly by the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplant.18  These recommendations are focused on risks faced by patients who have survived 6 or more months after transplantation. Most of these recommendations are derived from studies that have identified specific complications (and associated risk factors) in survivors. For pediatric survivors, the Children’s Oncology Group (COG) has developed long-term follow-up guidelines (www.survivorshipguidelines.org).19  COG guidelines are evidence-based (using established associations between therapeutic exposures and late effects to identify high-risk populations) and consensus-based (matching the magnitude of risk of complications with intensity of screening). Thus, for both the pediatric and adult BMT survivor population, we do not have evidence to support the frequency, modality, or timing of screening. Instead, we rely upon consensus arrived by experts in the field. This is because small samples and/or long latency of complications prevent us from conducting randomized clinical trials to determine what intensity/modality would be superior in early detection of complications or reduction in mortality.

Here, we describe our approach to risk-based screening for late-occurring or long-term complications in BMT survivors, using patient scenarios to illustrate our discussion. Because treatment exposures vary by primary diagnosis, BMT type (autologous or allogeneic) and patient age, a therapy-based approach was adopted (Table 1). We focus primarily on patients who have undergone BMT as adults, because a recent publication described recommendations for screening patients transplanted during childhood.20 

The patient is a 52-year-old male with a history of nodular sclerosing Hodgkin lymphoma (HL, stage IVA) diagnosed at age 34, treated with Adriamycin [doxorubicin], 300 mg/m2; bleomycin,120 units/m2; vinblastine, 72 mg/m2; and dacarbazine, 4.5 g/m2 chemotherapy, followed by involved field radiation to the mediastinum (3600 cGy). His disease relapsed 6 months after completion of therapy and he received salvage chemotherapy with ifosfamide (18 g/m2), carboplatin (1.6 g/m2), and etoposide (1 g/m2), followed by stem cell mobilization with granulocyte colony-stimulating factor, and autologous BMT with BiCNU (carmustine), 300 mg/m2; etoposide, 800 mg/m2; Ara-C (cytarabine), 1.6 g/m2; and melphalan, 140 mg/m2 conditioning. He tolerated the treatment well and was discharged home after a relatively uneventful course in the hospital. His medical care was transitioned to his primary care physician (PCP) 5 years after BMT. At age 48, he developed type 2 diabetes, managed with metformin and diet. At age 50, he developed prehypertension (systolic blood pressure [BP], 130 mm Hg; diastolic BP, 80 mm Hg), but was not treated. He now presents to his PCP with a 6-month history of worsening fatigue, shortness of breath, and lower extremity swelling. His clinical examination is notable for rales over the lung bases, and 1+ pitting pedal edema extending up to his ankles. Chest radiograph is concerning for cardiomegaly and pulmonary interstitial edema. Echocardiogram reveals an ejection fraction of 32%, and the patient is referred to the cardiologist for management of systolic heart failure (Table 2).

Discussion of patient 1

Among BMT survivors, cardiovascular disease (CVD; eg, CHF, stroke, myocardial infarction) is 1 of the leading causes of nonrelapse mortality.21  BMT survivors have a fourfold increased risk of developing CVD when compared with the general population.22  Median age at first cardiovascular event is 53 years of age,7  lower than that observed in the general population (67 years of age).23  Pre-BMT anthracycline chemotherapy and/or mediastinal radiation are the best described risk factors for late-occurring CHF.4,5,7,21  In autologous BMT survivors, cumulative anthracycline dose ≥250 mg/m2 is associated with a 10-fold increased risk of CHF.5  BMT survivors have a twofold increased risk of developing hypertension, diabetes, or dyslipidemia as compared with age- and sex-matched controls.6,22  Exposure to total body irradiation (TBI) increases the risk for dyslipidemia and diabetes.6  The presence of hypertension among autologous BMT survivors with prior exposure to high-dose anthracyclines (≥250 mg/m2) increases the risk of CHF 35-fold when compared with those without anthracycline exposure or hypertension (Figure 2).5  Similarly, the risk of CHF is 27-fold increased for high-dose anthracycline recipients with diabetes (Figure 2).5  Thus, there is clear evidence that hypertension and diabetes serve as modifiers of anthracycline-related cardiac injury after BMT.5,22 

Figure 2.

Risk of congestive heart failure among 1244 autologous BMT recipients with and without hypertension and diabetes who received high-dose anthracyclines. The presence of hypertension among recipients of high-dose anthracyclines (≥250 mg/m2) resulted in a 35-fold increased risk of CHF; the risk was nearly 27-fold for high-dose anthracycline recipients with diabetes. DM, diabetes mellitus; HD, high-dose; HTN, hypertension. Adapted from Armenian et al.5 

Figure 2.

Risk of congestive heart failure among 1244 autologous BMT recipients with and without hypertension and diabetes who received high-dose anthracyclines. The presence of hypertension among recipients of high-dose anthracyclines (≥250 mg/m2) resulted in a 35-fold increased risk of CHF; the risk was nearly 27-fold for high-dose anthracycline recipients with diabetes. DM, diabetes mellitus; HD, high-dose; HTN, hypertension. Adapted from Armenian et al.5 

Close modal

In summary, the increased risk of CVD, coupled with the recognition that these complications develop earlier than would be expected in the general population, suggests an accelerated cardiovascular aging phenotype that may be initiated by pre-BMT therapeutic exposures and is worsened by post-BMT risk factors such as hypertension and diabetes.6  Recommendations for long-term monitoring18,20  range in intensity from a history and physical examination, with echocardiography reserved for clinical suspicion of cardiac compromise,18,24,25  to serial echocardiography through the life of a survivor, regardless of symptoms.26,27  Echocardiographic measures of cardiac function (eg, left ventricular ejection fraction, fractional shortening) are often derived from crude ventricular measurements and are late-occurring changes in the trajectory of disease.28  More sensitive markers of early cardiac dysfunction such as echocardiography-derived cardiac mechanics (eg, speckle tracking strain), tissue Doppler imaging, and 3-dimensional echocardiographic or cardiac magnetic resonance imaging have been incorporated into guidelines for evaluation of patients after cancer therapy.29,30  However, there have been no studies to demonstrate that early intervention based on change in subclinical markers of cardiac dysfunction, such as strain alone, can prevent the development of overt heart failure in cancer survivors. Given these limitations, a thorough history and physical examination (with attention to symptoms and signs of cardiac dysfunction, such as chest pain, shortness of breath, ankle swelling, decreased exercise tolerance, palpitations, and fainting/lightheadedness) should be part of the routine care of BMT survivors considered at high risk for CHF because of past exposure to cardiotoxic therapies.24  For individuals in whom there is concern for cardiac dysfunction, referral to a cardiologist is recommended. Importantly, BMT survivors should be educated regarding their long-term CVD risk, emphasizing the importance of early recognition of symptoms of cardiac dysfunction so that appropriate interventions (eg, angiotensin-converting enzyme inhibitors, β-blockers) can be initiated per established guidelines.24,31 

Health care providers should regularly screen for and manage post-BMT cardiovascular risk factors such as hypertension and diabetes.18,24  In nononcology populations, aggressive management of hypertension (target systolic BP, <120 mm Hg)32  or diabetes (target hemoglobin A1C ≤6.5%)33  has been associated with decreased risk of CVD, a strategy worth considering in high-risk BMT survivors. There are emerging data among BMT survivors suggesting that adherence to a healthier lifestyle may attenuate risk of CVD; a diet rich in fruits and vegetables has been associated with reduced risk of diabetes and dyslipidemia, and increased physical activity has been associated with a decreased risk of hypertension.22  As such, adoption of a healthy lifestyle should be strongly encouraged for BMT survivors.

Clinical trials are needed to examine the timing and efficacy of interventions to reduce the risk of clinically overt cardiac disease in BMT survivors because the pathophysiology of these conditions often differ from that seen in nononcology populations. Such studies would help identify subsets of BMT patients who may derive the greatest benefit from more aggressive management of cardiovascular risk factors (eg, systolic BP <120 mm Hg, hemoglobin A1C ≤6.5%, low-density lipoprotein [LDL] <100 mg/dL, total cholesterol <200 mg/dL). Such efforts require multidisciplinary collaboration between PCPs, subspecialists (eg, cardiologists, endocrinologists), and BMT clinicians, allowing for personalized monitoring and intervention in survivors at highest risk for cardiac complications.

Monitoring for additional potential late complications

Therapeutic exposures place patient 1 at risk for pulmonary toxicity (bleomycin, carmustine, chest radiation), renal toxicity (ifosfamide, carboplatin), peripheral neuropathy (vinblastine, carboplatin), gonadal dysfunction (dacarbazine, ifosfamide, carmustine, melphalan, carboplatin), treatment-related myeloid neoplasm (t-MN; ifosfamide, melphalan, dacarbazine, carmustine, carboplatin, doxorubicin, etoposide), and subsequent solid neoplasms (chest radiation).

Pulmonary toxicity can develop with use of bleomycin, especially when chest radiation therapy and/or TBI are also part of the treatment. This toxicity develops months to years after completing therapy and usually manifests as cough and shortness of breath. High concentrations of oxygen exacerbates toxicity. One study found bleomycin lung damage in 18% of patients who received Adriamycin, bleomycin, vincristine, and dacarbazine for HL.34  For patients who have received potentially pulmonary toxic exposures (bleomycin, chest radiation, busulfan, nitrosoureas, TBI), we recommend pulmonary function tests at 1 year after BMT and then periodically as clinically indicated. Given the high risk for pulmonary infections in patients with a history of pulmonary toxic therapy, the pneumococcal vaccine series and yearly influenza vaccine are also recommended.

Renal toxicity can develop after BMT and may be associated with pretransplant exposures (ifosfamide, platinum-based chemotherapy, methotrexate, abdominal, and flank radiation), as well as TBI-containing BMT conditioning regimens, and exposures related to treatment of acute complications (eg, use of nephrotoxic antibiotics and antifungal agents) as well as ongoing treatment of GVHD (calcineurin inhibitors).35,36  Screening includes a renal function panel (serum creatinine, electrolytes) at 1 year following BMT, then as clinically indicated, and annual urinalysis for proteinuria, and annual BP monitoring.

Peripheral neuropathy associated with exposure to plant alkaloids (vincristine, vinblastine, taxanes) and heavy metals (carboplatin and cisplatin) is generally evident during or shortly after completion of therapy. Screening for at-risk patients should include a targeted history and physical examination with attention to the peripheral nervous system.37 

Gonadal dysfunction and subsequent neoplasms (t-MN, solid tumors), and related monitoring are presented in detail under discussions for patients 3 and 4, respectively.

The patient is a 40-year-old female with a history of acute myeloid leukemia, French-American-British M-2 with t(8;21) diagnosed at the age of 25. She was treated with 3+7 induction chemotherapy (daunorubicin 270 mg/m2 and cytarabine 1.4 g/m2) followed by consolidation with idarubicin (36 mg/m2), fludarabine (72 mg/m2), and cytarabine (5.3g/m2). She subsequently underwent an allogeneic BMT from an HLA-identical unrelated donor, conditioned with cyclophosphamide (3.2 g/m2) and TBI (1320 cGy in 11 fractions). She has a history of chronic GVHD (cGVHD) of the skin, which required treatment for 18 months after transplantation with a combination of corticosteroids and sirolimus. She presented to the clinic with insidious onset of fatigue, weight gain, constipation, and cold intolerance. Physical examination was positive for a weight gain of 7 pounds over the past year, but unremarkable otherwise. Her blood work revealed a thyroid stimulating hormone (TSH) level of 7.176 mIU/L (normal reference range, 0.470-4.680) and free thyroxine (FT4) level of 0.51 ng/dL (0.66-2.01). The patient was diagnosed with hypothyroidism and thyroid hormone replacement therapy was initiated. In addition, the patient had laboratory evidence of dyslipidemia (total cholesterol, 285 mg/dL [50-199]; LDL, 192 mg/dL [30-129]; high-density lipoprotein, 41 mg/dL [40-59]; triglyceride, 275 mg/dL [10-149]), and was managed with cholesterol-lowering medications and diet (Table 3).

Discussion of patient 2

Thyroid abnormalities are well-described after BMT38-43  and include compensated hypothyroidism (elevated TSH accompanied with normal FT4 levels) and overt hypothyroidism (elevated TSH and low FT4). Approximately 30% of patients develop overt hypothyroidism over a 28-year follow-up period.41  Hypothyroidism is related to radiation to the thyroid gland (neck/mediastinal radiation or TBI); younger age at exposure increases the risk.42,43  Symptoms include fatigue, weight gain, constipation, dry skin, and menstrual irregularities. Screening for thyroid dysfunction relies on a good history and physical examination and annual thyroid function tests (TSH, FT4). Survivors with abnormalities on screening evaluation should be referred to an endocrinologist for hormone replacement therapy, which may be dependent upon whether the hypothyroidism is compensated or overt44  because some cases of compensated hypothyroidism resolve spontaneously over time.45  The risk of dyslipidemia is increased in patients with hypothyroidism, necessitating appropriate management of the thyroid condition to treat dyslipidemia.

Monitoring for additional potential late complications

Additional therapeutic exposures place patient 2 at risk for anthracycline-related cardiomyopathy; cardiovascular risk factors (TBI, corticosteroids, calcineurin inhibitors); pulmonary toxicity (TBI); renal toxicity (TBI, calcineurin inhibitors); osteonecrosis (TBI, corticosteroids, calcineurin inhibitors); t-MN (cyclophosphamide, daunorubicin, idarubicin); and radiation-related solid tumors (TBI). She is also at risk for gonadal dysfunction (cyclophosphamide, TBI), osteoporosis (corticosteroids, calcineurin inhibitors), neurocognitive dysfunction (TBI, high-dose cytarabine), and cataracts (corticosteroids, TBI).

Gonadal dysfunction.

It has been shown that almost all females age 13 years or older at receipt of fractionated TBI develop ovarian failure, probably as a result of decreased reserve of primordial follicles.46,47  Exposure to cyclophosphamide is also associated with gonadal failure.48  Screening for gonadal failure includes a detailed history (primary or secondary amenorrhea, menstrual irregularity, and pregnancies or problems with fertility), physical examination, and serum gonadotropin (luteinizing hormone [LH], follicle stimulating hormone [FSH]) and estradiol levels. High LH and FSH accompanied by low estradiol levels suggest primary ovarian failure. Irreversibility of ovarian function after BMT in most patients highlights the need for timely hormonal replacement therapy to prevent osteoporosis and other complications resulting from lack of gonadal hormones.

Osteoporosis.

BMT recipients are at risk for osteoporosis.9  The decreased bone mineral density seen in BMT survivors is typically resulting from treatment of GVHD with corticosteroids or calcineurin inhibitors49 ; physical inactivity and low dietary intake of calcium50 ; and/or uncorrected hypogonadism.51-53  Bone loss after BMT nadirs at 6 to 24 months.54,55  The incidence of osteoporosis approaches 20% at 2 years.56,57  Bone loss increases the risk of fractures; nontraumatic fractures have been observed in 10% of patients within 3 years after BMT.56  Transplant survivorship guidelines recommend assessment of bone mineral density with dual-energy x-ray absorptiometry (DXA) scan within 1 year after BMT, especially in those receiving allogeneic BMT and/or patients treated with prolonged corticosteroids and calcineurin inhibitors.18 

Neurocognitive dysfunction.

TBI is associated with neurocognitive impairment, especially for those <50 years of age at exposure.58  The risk is also increased among those who received cranial radiation before BMT. Specific domains affected include executive functioning, attention, memory, and processing speed. Although neurocognitive function improves from 1 to 5 years after BMT, deficits remain for >40% of survivors.59  We recommend annual screening for cognitive/vocational difficulties and formal neuropsychological evaluation if difficulties are identified.

Cataracts.

Radiation (TBI or cranial radiation before BMT) and exposure to corticosteroids are associated with premature cataracts.60,61  The 10-year incidence of cataracts is higher among patients treated with single-dose TBI (60%), slightly lower among those who receive <6 fractions (43%), and significantly lower among those treated with >6 fractions (7%).62  Factors associated with increased risk of cataracts are older age, higher radiation dose rate (>0.04 Gy/min), allogeneic BMT, prolonged corticosteroids, and use of single-dose TBI.60-62  Annual ophthalmologic examination in patients at risk for cataracts is recommended.

The patient is a 25-year-old male diagnosed with stage IV Burkitt lymphoma at age 21. He was treated with French LMB-style therapy and received the following cumulative chemotherapy doses: cyclophosphamide (8.5 g/m2), methotrexate (32 g/m2), etoposide (2.1 g/m2), cytarabine (17.5 g/m2), doxorubicin (240 mg/m2), prednisone (780 mg/m2), vincristine (8 mg/m2), and triple intrathecal therapy. He was in remission for 11 months, but developed a recurrence, for which he received ifosfamide, 18 g/m2; carboplatin, 1.6 g/m2; and etoposide, 1 g/m2, followed by allogeneic BMT from an HLA-identical sibling donor (conditioning: cyclophosphamide [3.2 g/m2] and TBI [1320 cGy in 11 fractions]). He developed cGVHD of the skin, for which he has been receiving treatment with a combination of corticosteroids and sirolimus for the past 24 months. He presents to the clinic with complaints of pain in the left hip. Radiograph of the hip shows partial collapse of the left femoral head with sclerosis (Table 4).

Discussion of patient 3

The complaint of left hip pain and the associated radiologic findings are consistent with osteonecrosis of the left femoral capital epiphysis, a complication associated with significant morbidity often requiring surgery. The risk of osteonecrosis is highest among unrelated donor recipients, approaching 15% at 10 years after BMT, and lowest among autologous BMT survivors, in whom the risk is less than 3% (Figure 3).8  The femoral head is most commonly affected; others include the knee and shoulder joints. Risk factors for osteonecrosis include male sex, GVHD therapy with corticosteroids or calcineurin inhibitors, and use of TBI for conditioning.8  The association with corticosteroids increases with cumulative dose.63  Clinical anticipation in at-risk survivors with a careful history and physical examination is the cornerstone of screening. Prompt radiologic evaluation with appropriate interventions can reduce the morbidity related to pain and lack of mobility.

Figure 3.

Late osteonecrosis by BMT donor type in 1346 BMT recipients. The cumulative incidence of osteonecrosis was 2.9% after autologous BMT, 5.4% after allogeneic matched related BMT, and 15% after unrelated donor BMT. Adapted from Campbell et al.8 

Figure 3.

Late osteonecrosis by BMT donor type in 1346 BMT recipients. The cumulative incidence of osteonecrosis was 2.9% after autologous BMT, 5.4% after allogeneic matched related BMT, and 15% after unrelated donor BMT. Adapted from Campbell et al.8 

Close modal

Monitoring for additional potential late complications

Additional therapeutic exposures place patient 3 at risk for anthracycline-related cardiomyopathy, pulmonary toxicity (TBI), cardiovascular risk factors (TBI, calcineurin inhibitors, corticosteroids), renal toxicity (ifosfamide, carboplatin, methotrexate, TBI, calcineurin inhibitors), and peripheral neuropathy (vincristine, carboplatin); hypothyroidism (TBI), neurocognitive dysfunction (TBI, high-dose methotrexate and cytarabine), osteoporosis and related fractures (corticosteroids, calcineurin inhibitors, high-dose methotrexate), osteonecrosis (TBI, corticosteroids, calcineurin inhibitors), cataracts (TBI, corticosteroids), and t-MN (alkylators and topoisomerase II inhibitors) and radiation-related solid tumors. He is also at risk for gonadal dysfunction (cyclophosphamide, ifosfamide, carboplatin, TBI). Additionally, given the active cGVHD requiring immunosuppressive therapy, this patient is at risk for functional asplenia and associated life-threatening infections with encapsulated organisms and should receive vaccines specified in Table 4 and anticipatory health education regarding infection-related risks.64-66 

Gonadal failure.

Exposure to cyclophosphamide (11.7 g/m2), ifosfamide (1 g/m2), and TBI (1320 cGy) places this patient at risk for gonadal failure. The risk of gonadal failure increases with cumulative doses of gonadotoxic therapies. Screening for gonadal failure includes a detailed history (assessing for decreased libido and fertility problems), serum gonadotropin and testosterone levels, and semen analysis (if the patient wishes to know his fertility status). High LH and FSH accompanied with low testosterone suggest primary gonadal failure. In men with low testosterone, referral to an endocrinologist for testosterone replacement therapy is indicated. In men with infertility or subfertility, referral to a reproductive endocrinologist may be indicated.

The patient is a 33-year-old female diagnosed with nodular sclerosing HL, stage IVB at age 18, presenting with bilateral supraclavicular and mediastinal disease, along with liver and spleen involvement. She was treated with cyclophosphamide (3.6 g/m2), vincristine (8.4 mg/m2), prednisone (3.4 g/m2), procarbazine (4.2 g/m2), doxorubicin (210 mg/m2), bleomycin (60 units/m2), and vinblastine (36 mg/m2). She had residual disease at the end of planned therapy. She underwent stem cell mobilization with etoposide (1.0 g/m2), cyclophosphamide (1.5 g/m2), and granulocyte colony-stimulating factor, followed by tandem peripheral blood stem cell transplant (conditioning: melphalan [150 mg/m2] and cyclophosphamide [3.3 g/m2]; etoposide [1.8 g/m2], and TBI [1200 cGy in 10 fractions]). She presented for a routine follow-up visit with a palpable 2-cm mass in the upper outer quadrant of the right breast. Mammography revealed focal asymmetry in the right upper outer region. High-resolution real-time ultrasound scan revealed an irregular hypervascular solid mass seen in the right breast at 10 o'clock position, corresponding to the palpable area. Biopsy revealed invasive ductal carcinoma. Tumor cells were positive for estrogen and progesterone receptors and were human epidermal growth factor receptor 2–positive (Table 5).

Discussion of patient 4

Exposure to chest radiation in pubertal females increases the risk of subsequent breast cancer.67  There is a linear dose-response relation between increasing radiation dose and risk of subsequent breast cancer.68  Whole-lung radiation also increases risk, demonstrating the importance of radiation volume in addition to dose.69  The association between TBI and subsequent breast cancer was examined in the setting of allogeneic BMT,70  placing allogeneic BMT survivors at a 2.2-fold increased risk of developing breast cancer when compared with age- and sex-matched general population. The median latency from BMT to breast cancer was 12.5 years. The incidence was higher among those exposed to TBI (17% vs 3%) and among those exposed to TBI at age <18 years.

SNs are classified into 3 distinct groups: (1) therapy-related myeloid neoplasms (t-MN); (2) lymphoma (including lymphoproliferative disorders); and (3) solid tumors.

t-MN.

t-MN is a major cause of nonrelapse mortality after autologous BMT for HL and NHL.2,12  t-MN usually develops 4 to 7 years after alkylating agent exposure (Figure 4). Patients frequently present with cytopenias and multilineage dysplasia, with abnormalities involving chromosomes 5 (−5/del[5q]) and 7 (−7/del[7q]). t-MN secondary to topoisomerase II inhibitors presents as overt leukemia, without a preceding myelodysplastic phase. The latency is brief (6 months to 5 years) and is associated with balanced translocations involving chromosome bands 11q23 or 21q22. The risk of t-MN increases with age at BMT,3  pretransplantation therapy with alkylating agents, topoisomerase II inhibitors, radiation, use of peripheral blood stem cells, stem cell mobilization with etoposide, difficult stem cell harvests, conditioning with TBI, and (lower) number of CD34+ cells infused.2,3  The common and nonspecific nature of cytopenias after autologous BMT has resulted in the development of criteria for diagnosing t-MN after BMT: (1) significant marrow dysplasia in at least 2 cell lines, (2) unexplained peripheral cytopenias, and (3) blasts defined by French-American-British classification.71  Presence of a clonal cytogenetic abnormality in addition to morphologic criteria of dysplasia may aid in making this diagnosis.

Figure 4.

Subsequent neoplasms after BMT from a single transplant center. The cumulative incidence of solid subsequent neoplasms is 15.2% at 25 years after autologous or allogeneic BMT. The cumulative incidence of t-MN is 6.5% at 15 years after autologous BMT. Adapted from Bhatia and Bhatia.80 

Figure 4.

Subsequent neoplasms after BMT from a single transplant center. The cumulative incidence of solid subsequent neoplasms is 15.2% at 25 years after autologous or allogeneic BMT. The cumulative incidence of t-MN is 6.5% at 15 years after autologous BMT. Adapted from Bhatia and Bhatia.80 

Close modal

Solid SNs.

In addition to subsequent breast cancer, our patient is also at risk for other solid SNs. Compared with an age- and sex-matched general population, BMT survivors carry a twofold increased risk of solid SNs.1  The risk of solid SNs increases over time (Figure 4).72  Solid SNs are associated with exposure to pre-BMT radiation or TBI and includes melanoma, basal cell carcinoma (BCC), salivary gland tumors, and thyroid, breast, bone, and connective tissue cancers, those related to cGVHD (squamous cell carcinoma [SCC] of the skin), or those related to chronic viral infection in the setting of immunosuppression (human papillomavirus: oropharyngeal or cervix cancer; and hepatitis B or C: hepatocellular carcinoma). A large study found the 20-year cumulative incidence of BCC and SCC as 6.5% and 3.4%, respectively, after allogeneic BMT.73  TBI increases the risk of BCC, particularly among young patients.74  Acute GVHD increases the risk of SCC; cGVHD increases the risk of both BCC and SCC.1  BMT recipients are at a threefold increased risk of thyroid cancer when compared with an age- and sex-matched general population.75  Age younger than 10 years at radiation, female sex, and cGVHD are associated with increased risk. Thyroid cancer develops after a latency of approximately 8 to 10 years.

Screening BMT survivors for SNs is important; however, evidence regarding frequency/intensity/modality remains limited. General recommendations are for the most part based on guidelines for the general population and certain high-risk subpopulations.76  Pre-BMT exposures (chest or cranial radiation, alkylating agents, topoisomerase II inhibitors) or BMT-related exposures (TBI, cGVHD) lead to elevated risks of SNs and must be considered in the screening strategies. We recommend annual history and physical examination, including oral cavity, uterine cervix, external genitalia, and full skin examination, colonoscopy every 5 years (minimum) beginning 10 years after radiation or age 35 years, and for those with palpable thyroid nodules, an ultrasound-guided fine needle aspiration. Specifically in regard to breast cancer screening recommendations for patient 4, COG guidelines indicate that semi-annual clinical breast examination and annual mammography and breast magnetic resonance imaging should be considered for patients with a history of TBI, beginning at age 25 or 8 years after radiation, whichever occurs last.19 

Monitoring for additional potential late complications

Additional key therapeutic exposures place patient 4 at risk for cardiomyopathy (anthracycline), cardiovascular risk factors (TBI, prednisone), pulmonary toxicity (bleomycin, TBI), renal toxicity (TBI), and peripheral neuropathy (vinblastine, vincristine); gonadal dysfunction (cyclophosphamide, melphalan, procarbazine, TBI), hypothyroidism (TBI), neurocognitive dysfunction (TBI), osteoporosis and related fractures (prednisone), and cataracts (TBI, prednisone); as well as osteonecrosis (TBI, prednisone).

Exposure to pre-BMT treatment, high-intensity BMT-related treatment and immunosuppression after BMT increase the burden of morbidity after BMT. The adoption of maintenance-type therapy (eg, immunotherapy for lymphoma, lenalidomide for multiple myeloma) increases the risk of new complications (eg, hypogammaglobulinemia after rituximab77,78 ) that may develop after BMT.

This high burden of morbidity necessitates that strategies be developed for early detection of these complications. We have shown that although the vast majority of BMT survivors remain engaged with the health care system, the burden of providing complex and nuanced care falls upon PCPs because only a small minority of patients returns to the transplanting institutions for long-term care.79  This is not an ideal scenario because the PCPs are not equipped to handle these situations, nor are they comfortable in handling them because of time constraints as well as the challenge of staying abreast with issues faced by BMT survivors.

The care of the growing population of transplant survivors can be handled in 1 of 2 possible ways. The first option is to have specialized clinics for the long-term management of BMT survivors, offering risk-based screening for early detection of long-term complications. Several transplant programs offer this service to the survivors. The clinics often staffed by advanced practice professionals, offering risk-based screening for long-term complications. Patients are triaged to appropriate specialists if they are identified to have a complication. The second option is for dedicated PCPs with special interest in cancer survivorship issues to take on the responsibility of managing such a patient. A third option would be a hybrid approach in which the specialized clinics at transplant centers partner with PCPs in the community to optimize the long-term care of the transplant survivors.

No matter how or where BMT survivors receive long-term care, there is a need for standardized recommendations. It is important to note however that, although we do have evidence supporting the relationship between therapeutic exposures and long-term complications, we do not have evidence to support the frequency or modality of the screening tests. Instead, we rely upon consensus arrived by experts in the field. This is because limitations of sample size and/or long of complications preclude the ability to conduct randomized clinical trials to determine what frequency/intensity/modality would be superior in ensuring early detection or reduction in mortality.

Development of consensus-based guidelines represents a first step in standardizing long-term follow-up of BMT survivors. The overall goal of standardized guidelines is early identification of treatment-related complications, allowing for early intervention with resultant reduction in morbidity and mortality and attendant reduction in health care costs. To achieve the benefits of early detection and prevention of life-threatening complications, BMT survivors should undergo regular comprehensive physical examinations that include screening for functional and psychosocial consequences of treatment and education regarding key aspects of health promotion. The next important step is to ensure that the existing guidelines are disseminated and accepted by all health care providers caring for BMT survivors as well as by payers that reimburse for the costs of the screening tests. Adherence to standardized screening recommendations, the yield of screening, and the cost-effectiveness of standardized follow-up of BMT survivors will provide future evidence for guideline refinement.

Contribution: S.B. conceived and designed the study; and S.B., S.H.A., and W.L. acquired, analyzed, and interpreted the data; wrote the manuscript; and gave final approval for the manuscript.

Conflict-of-interest disclosure. The authors declare no competing conflicts of interest.

Correspondence: Smita Bhatia, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, 1600 7th Ave S, Lowder 500, Birmingham, AL 35233; e-mail: sbhatia@peds.uab.edu.

1.
Rizzo
JD
,
Curtis
RE
,
Socié
G
, et al
.
Solid cancers after allogeneic hematopoietic cell transplantation
.
Blood
.
2009
;
113
(
5
):
1175
-
1183
.
2.
Krishnan
A
,
Bhatia
S
,
Slovak
ML
, et al
.
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
.
Blood
.
2000
;
95
(
5
):
1588
-
1593
.
3.
Bhatia
S
,
Ramsay
NK
,
Steinbuch
M
, et al
.
Malignant neoplasms following bone marrow transplantation
.
Blood
.
1996
;
87
(
9
):
3633
-
3639
.
4.
Armenian
SH
,
Sun
CL
,
Francisco
L
, et al
.
Late congestive heart failure after hematopoietic cell transplantation
.
J Clin Oncol
.
2008
;
26
(
34
):
5537
-
5543
.
5.
Armenian
SH
,
Sun
CL
,
Shannon
T
, et al
.
Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation
.
Blood
.
2011
;
118
(
23
):
6023
-
6029
.
6.
Armenian
SH
,
Sun
CL
,
Vase
T
, et al
.
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
.
Blood
.
2012
;
120
(
23
):
4505
-
4512
.
7.
Armenian
SH
,
Sun
CL
,
Mills
G
, et al
.
Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2010
;
16
(
8
):
1138
-
1144
.
8.
Campbell
S
,
Sun
CL
,
Kurian
S
, et al
.
Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation
.
Cancer
.
2009
;
115
(
18
):
4127
-
4135
.
9.
Tauchmanovà
L
,
Colao
A
,
Lombardi
G
,
Rotoli
B
,
Selleri
C
.
Bone loss and its management in long-term survivors from allogeneic stem cell transplantation
.
J Clin Endocrinol Metab
.
2007
;
92
(
12
):
4536
-
4545
.
10.
Sun
CL
,
Francisco
L
,
Kawashima
T
, et al
.
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study
.
Blood
.
2010
;
116
(
17
):
3129
-
3139, quiz 3377
.
11.
Sun
CL
,
Kersey
JH
,
Francisco
L
, et al
.
Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study
.
Biol Blood Marrow Transplant
.
2013
;
19
(
7
):
1073
-
1080
.
12.
Bhatia
S
,
Robison
LL
,
Francisco
L
, et al
.
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the one Marrow Transplant Survivor Study
.
Blood
.
2005
;
105
(
11
):
4215
-
4222
.
13.
Bhatia
S
,
Francisco
L
,
Carter
A
, et al
.
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
.
Blood
.
2007
;
110
(
10
):
3784
-
3792
.
14.
Atsuta
Y
,
Hirakawa
A
,
Nakasone
H
, et al
;
Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation
.
Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2016
;
22
(
9
):
1702
-
1709
.
15.
Goldman
JM
,
Majhail
NS
,
Klein
JP
, et al
.
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase
.
J Clin Oncol
.
2010
;
28
(
11
):
1888
-
1895
.
16.
Vajdic
CM
,
Mayson
E
,
Dodds
AJ
, et al
;
CAST study investigators
.
Second cancer risk and late mortality in adult Australians receiving allogeneic hematopoietic stem cell transplantation: a population-based cohort study
.
Biol Blood Marrow Transplant
.
2016
;
22
(
5
):
949
-
956
.
17.
Vanderwalde
AM
,
Sun
CL
,
Laddaran
L
, et al
.
Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies
.
Leukemia
.
2013
;
27
(
5
):
1139
-
1145
.
18.
Majhail
NS
,
Rizzo
JD
,
Lee
SJ
, et al
;
Center for International Blood and Marrow Transplant Research; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation; Asia-Pacific Blood and Marrow Transplantation Group; Bone Marrow Transplant Society of Australia and New Zealand; East Mediterranean Blood and Marrow Transplantation Group; Sociedade Brasileira de Transplante de Medula Ossea
.
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
.
Bone Marrow Transplant
.
2012
;
47
(
3
):
337
-
341
.
19.
Landier
W
,
Bhatia
S
,
Eshelman
DA
, et al
.
Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group long-term follow-up guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline
.
J Clin Oncol
.
2004
;
22
(
24
):
4979
-
4990
.
20.
Chow
EJ
,
Anderson
L
,
Baker
KS
, et al
.
Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children’s Oncology Group Report
.
Biol Blood Marrow Transplant
.
2016
;
22
(
5
):
782
-
795
.
21.
Armenian
SH
,
Chow
EJ
.
Cardiovascular disease in survivors of hematopoietic cell transplantation
.
Cancer
.
2014
;
120
(
4
):
469
-
479
.
22.
Chow
EJ
,
Baker
KS
,
Lee
SJ
, et al
.
Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation
.
J Clin Oncol
.
2014
;
32
(
3
):
191
-
198
.
23.
Greenland
P
,
Alpert
JS
,
Beller
GA
, et al
;
American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
.
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
.
Circulation
.
2010
;
122
(
25
):
e584
-
e636
.
24.
Armenian
SH
,
Lacchetti
C
,
Barac
A
, et al
.
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline
.
J Clin Oncol
.
2017
;
35
(
8
):
893
-
911
.
25.
Carver
JR
,
Shapiro
CL
,
Ng
A
, et al
;
ASCO Cancer Survivorship Expert Panel
.
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects
.
J Clin Oncol
.
2007
;
25
(
25
):
3991
-
4008
.
26.
Armenian
SH
,
Hudson
MM
,
Mulder
RL
, et al
;
International Late Effects of Childhood Cancer Guideline Harmonization Group
.
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
.
Lancet Oncol
.
2015
;
16
(
3
):
e123
-
e136
.
27.
Shankar
SM
,
Marina
N
,
Hudson
MM
, et al
;
Cardiovascular Disease Task Force of the Children’s Oncology Group
.
Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group
.
Pediatrics
.
2008
;
121
(
2
):
e387
-
e396
.
28.
Ewer
MS
,
Lenihan
DJ
.
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
J Clin Oncol
.
2008
;
26
(
8
):
1201
-
1203
.
29.
Plana
JC
,
Galderisi
M
,
Barac
A
, et al
.
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
J Am Soc Echocardiogr
.
2014
;
27
(
9
):
911
-
939
.
30.
Zamorano
JL
,
Lancellotti
P
,
Rodriguez Muñoz
D
, et al
;
Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG)
.
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)
.
Eur Heart J
.
2016
;
37
(
36
):
2768
-
2801
.
31.
Hunt
SA
,
Abraham
WT
,
Chin
MH
, et al
;
American College of Cardiology Foundation; American Heart Association
.
2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
.
J Am Coll Cardiol
.
2009
;
53
(
15
):
e1
-
e90
.
32.
Wright
JT
Jr
,
Williamson
JD
,
Whelton
PK
, et al
;
SPRINT Research Group
.
A randomized trial of intensive versus standard blood-pressure control
.
N Engl J Med
.
2015
;
373
(
22
):
2103
-
2116
.
33.
Rodbard
HW
,
Jellinger
PS
,
Davidson
JA
, et al
.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control
.
Endocr Pract
.
2009
;
15
(
6
):
540
-
559
.
34.
Martin
WG
,
Ristow
KM
,
Habermann
TM
,
Colgan
JP
,
Witzig
TE
,
Ansell
SM
.
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma
.
J Clin Oncol
.
2005
;
23
(
30
):
7614
-
7620
.
35.
Ellis
MJ
,
Parikh
CR
,
Inrig
JK
,
Kanbay
M
,
Patel
UD
.
Chronic kidney disease after hematopoietic cell transplantation: a systematic review [published corrections appears in Am J Transplant. 2009;9(4):865]
.
Am J Transplant
.
2008
;
8
(
11
):
2378
-
2390
.
36.
Choi
M
,
Sun
CL
,
Kurian
S
, et al
.
Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation
.
Cancer
.
2008
;
113
(
7
):
1580
-
1587
.
37.
Hilkens
PH
,
ven den Bent
MJ
.
Chemotherapy-induced peripheral neuropathy
.
J Peripher Nerv Syst
.
1997
;
2
(
4
):
350
-
361
.
38.
Myers
KC
,
Howell
JC
,
Wallace
G
, et al
.
Poor growth, thyroid dysfunction and vitamin D deficiency remain prevalent despite reduced intensity chemotherapy for hematopoietic stem cell transplantation in children and young adults
.
Bone Marrow Transplant
.
2016
;
51
(
7
):
980
-
984
.
39.
Sánchez-Ortega
I
,
Canals
C
,
Peralta
T
, et al
.
Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation
.
Bone Marrow Transplant
.
2012
;
47
(
2
):
296
-
298
.
40.
Medinger
M
,
Zeiter
D
,
Heim
D
, et al
.
Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
.
Leuk Res
.
2017
;
58
:
43
-
47
.
41.
Sanders
JE
,
Hoffmeister
PA
,
Woolfrey
AE
, et al
.
Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience
.
Blood
.
2009
;
113
(
2
):
306
-
308
.
42.
Ishiguro
H
,
Yasuda
Y
,
Tomita
Y
, et al
.
Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence
.
J Clin Endocrinol Metab
.
2004
;
89
(
12
):
5981
-
5986
.
43.
Berger
C
,
Le-Gallo
B
,
Donadieu
J
, et al
.
Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia
.
Bone Marrow Transplant
.
2005
;
35
(
10
):
991
-
995
.
44.
Surks
MI
,
Ortiz
E
,
Daniels
GH
, et al
.
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management
.
JAMA
.
2004
;
291
(
2
):
228
-
238
.
45.
Al-Fiar
FZ
,
Colwill
R
,
Lipton
JH
,
Fyles
G
,
Spaner
D
,
Messner
H
.
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants
.
Bone Marrow Transplant
.
1997
;
19
(
10
):
1019
-
1022
.
46.
Sanders
JE
.
Growth and development after hematopoietic cell transplant in children
.
Bone Marrow Transplant
.
2008
;
41
(
2
):
223
-
227
.
47.
Sanders
JE
;
The Seattle Marrow Transplant Team
.
The impact of marrow transplant preparative regimens on subsequent growth and development
.
Semin Hematol
.
1991
;
28
(
3
):
244
-
249
.
48.
Mertens
AC
,
Ramsay
NK
,
Kouris
S
,
Neglia
JP
.
Patterns of gonadal dysfunction following bone marrow transplantation
.
Bone Marrow Transplant
.
1998
;
22
(
4
):
345
-
350
.
49.
Stern
JM
,
Chesnut
CH
III
,
Bruemmer
B
, et al
.
Bone density loss during treatment of chronic GVHD
.
Bone Marrow Transplant
.
1996
;
17
(
3
):
395
-
400
.
50.
Suzuki
Y
,
Whiting
SJ
,
Davison
KS
,
Chilibeck
PD
.
Total calcium intake is associated with cortical bone mineral density in a cohort of postmenopausal women not taking estrogen
.
J Nutr Health Aging
.
2003
;
7
(
5
):
296
-
299
.
51.
Irwig
MS
.
Male hypogonadism and skeletal health
.
Curr Opin Endocrinol Diabetes Obes
.
2013
;
20
(
6
):
517
-
522
.
52.
Tuck
SP
,
Francis
RM
.
Testosterone, bone and osteoporosis
.
Front Horm Res
.
2009
;
37
:
123
-
132
.
53.
Popat
VB
,
Calis
KA
,
Vanderhoof
VH
, et al
.
Bone mineral density in estrogen-deficient young women
.
J Clin Endocrinol Metab
.
2009
;
94
(
7
):
2277
-
2283
.
54.
Schulte
CM
,
Beelen
DW
.
Bone loss following hematopoietic stem cell transplantation: a long-term follow-up
.
Blood
.
2004
;
103
(
10
):
3635
-
3643
.
55.
Mattano
LA
Jr
.
Strategic approaches to osteoporosis in transplantation
.
Pediatr Transplant
.
2004
;
8
(
Suppl 5
):
51
-
55
.
56.
Stern
JM
,
Sullivan
KM
,
Ott
SM
, et al
.
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study
.
Biol Blood Marrow Transplant
.
2001
;
7
(
5
):
257
-
264
.
57.
Schimmer
AD
,
Mah
K
,
Bordeleau
L
, et al
.
Decreased bone mineral density is common after autologous blood or marrow transplantation
.
Bone Marrow Transplant
.
2001
;
28
(
4
):
387
-
391
.
58.
Sharafeldin
N
,
Bosworth
A
,
Chen
Y
, et al
.
Single Nucleotide Polymorphisms (SNPs) Associated with Cognitive Impairment in Patients Treated With Hematopoietic Cell Transplantation (HCT): A Longitudinal Study
.
San Diego
:
American Society of Hematology
;
2016
.
59.
Syrjala
KL
,
Artherholt
SB
,
Kurland
BF
, et al
.
Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years
.
J Clin Oncol
.
2011
;
29
(
17
):
2397
-
2404
.
60.
Zierhut
D
,
Lohr
F
,
Schraube
P
, et al
.
Cataract incidence after total-body irradiation
.
Int J Radiat Oncol Biol Phys
.
2000
;
46
(
1
):
131
-
135
.
61.
van Kempen-Harteveld
ML
,
Belkacémi
Y
,
Kal
HB
,
Labopin
M
,
Frassoni
F
.
Dose-effect relationship for cataract induction after single-dose total body irradiation and bone marrow transplantation for acute leukemia
.
Int J Radiat Oncol Biol Phys
.
2002
;
52
(
5
):
1367
-
1374
.
62.
Belkacemi
Y
,
Labopin
M
,
Vernant
JP
, et al
.
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation
.
Int J Radiat Oncol Biol Phys
.
1998
;
41
(
3
):
659
-
668
.
63.
McAvoy
S
,
Baker
KS
,
Mulrooney
D
, et al
.
Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2010
;
16
(
9
):
1231
-
1236
.
64.
Carpenter
PA
,
Englund
JA
.
How I vaccinate blood and marrow transplant recipients
.
Blood
.
2016
;
127
(
23
):
2824
-
2832
.
65.
Tomblyn
M
,
Chiller
T
,
Einsele
H
, et al
;
Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention
.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Bone Marrow Transplant. 2010;16(2):294]
.
Biol Blood Marrow Transplant
.
2009
;
15
(
10
):
1143
-
1238
.
66.
Wingard
JR
,
Majhail
NS
,
Brazauskas
R
, et al
.
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
.
J Clin Oncol
.
2011
;
29
(
16
):
2230
-
2239
.
67.
Henderson
TO
,
Amsterdam
A
,
Bhatia
S
, et al
.
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer
. Ann Intern Med.
2010
;152(7):444-455.
68.
Inskip
PD
,
Robison
LL
,
Stovall
M
, et al
.
Radiation dose and breast cancer risk in the childhood cancer survivor study
.
J Clin Oncol
.
2009
;
27
(
24
):
3901
-
3907
.
69.
Moskowitz
CS
,
Chou
JF
,
Wolden
SL
, et al
.
Breast cancer after chest radiation therapy for childhood cancer
.
J Clin Oncol
.
2014
;
32
(
21
):
2217
-
2223
.
70.
Friedman
DL
,
Rovo
A
,
Leisenring
W
, et al
;
FHCRC; EBMT-Late Effect Working Party
.
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party
.
Blood
.
2008
;
111
(
2
):
939
-
944
.
71.
Gilliland
DG
,
Gribben
JG
.
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation
.
Biol Blood Marrow Transplant
.
2002
;
8
(
1
):
9
-
16
.
72.
Bhatia
S
,
Louie
AD
,
Bhatia
R
, et al
.
Solid cancers after bone marrow transplantation
.
J Clin Oncol
.
2001
;
19
(
2
):
464
-
471
.
73.
Leisenring
W
,
Friedman
DL
,
Flowers
ME
,
Schwartz
JL
,
Deeg
HJ
.
Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation
.
J Clin Oncol
.
2006
;
24
(
7
):
1119
-
1126
.
74.
Schwartz
JL
,
Kopecky
KJ
,
Mathes
RW
,
Leisenring
WM
,
Friedman
DL
,
Deeg
HJ
.
Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation
.
Radiat Res
.
2009
;
171
(
2
):
155
-
163
.
75.
Cohen
A
,
Rovelli
A
,
Merlo
DF
, et al
.
Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study
.
J Clin Oncol
.
2007
;
25
(
17
):
2449
-
2454
.
76.
Smith
RA
,
Manassaram-Baptiste
D
,
Brooks
D
, et al
.
Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening
.
CA Cancer J Clin
.
2014
;
64
(
1
):
30
-
51
.
77.
De Angelis
F
,
Tosti
ME
,
Capria
S
, et al
.
Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study
.
Leuk Res
.
2015
;
39
(
12
):
1382
-
1388
.
78.
Casulo
C
,
Maragulia
J
,
Zelenetz
AD
.
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
.
Clin Lymphoma Myeloma Leuk
.
2013
;
13
(
2
):
106
-
111
.
79.
Shankar
SM
,
Carter
A
,
Sun
CL
, et al
.
Health care utilization by adult long-term survivors of hematopoietic cell transplant: report from the Bone Marrow Transplant Survivor Study
.
Cancer Epidemiol Biomarkers Prev
.
2007
;
16
(
4
):
834
-
839
.
80.
Bhatia
S
,
Bhatia
R
.
Subsequent malignant neoplasms after hematopoietic cell transplantation. In:
Forman
SJ
,
Negrin
RS
,
Antin
JH
,
Appelbaum
FR
, eds
. Thomas' Hematopoietic Cell Transplantation. 5th ed.
New York, NY
:
John Wiley & Sons, Ltd.
;
2016
:
1275
-
1289
.
Sign in via your Institution